Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

ABSTRACT:

Introduction

Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists.

Methods

An online, self-administered survey was fielded to pulmonologists between April 10 and May 17, 2017. Pulmonologists were included if they spent > 20% of their time in direct patient care and had ≥ 5 patients with IPF on antifibrotic therapy. Participants answered questions regarding initiation of pirfenidone, dose titration, and management of potential AEs.

Results

A total of 169 pulmonologists participated. Gastrointestinal (GI) intolerance was the most important factor in i

SUBMITTER: Wencel ML 

PROVIDER: S-EPMC6967051 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature